Cargando…
Effectiveness of Mavrilimumab in Viral Infections Including SARS-CoV-2 Infection - A Brief Review
Hyperinflammation and cytokine storm has been noted as a poor prognostic factor in patients with severe pneumonia related to coronavirus disease 2019 (COVID-19). In COVID-19, pathogenic myeloid cell overactivation is found to be a vital mediator of damage to tissues, hypercoagulability, and the cyto...
Autores principales: | Bhatt, Kinal, Garimella, Radhika, Taugir, Rahima, Mehta, Isha, Jamal, Muhammad, Vijayan, Rupalakshmi, Offor, Rita, Nwankwo, Kanayo, Arif, Uroosa, Waheed, Khurram, Kumari, Priyanka, Lathiya, Maulik, Michel, George, Pandya, Naushira, Halpern, John, Nasir, Hassan, Sanchez-Gonzalez, Marcos A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Society of Infectious Diseases; Korean Society for Antimicrobial Therapy; The Korean Society for AIDS
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8032909/ https://www.ncbi.nlm.nih.gov/pubmed/34409778 http://dx.doi.org/10.3947/ic.2020.0109 |
Ejemplares similares
-
Mavrilimumab for severe COVID-19
por: Khan, Adil Rashid, et al.
Publicado: (2020) -
Mavrilimumab for severe COVID-19
por: Pourhoseingholi, Mohamad Amin, et al.
Publicado: (2020) -
Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis
por: Burmester, Gerd R, et al.
Publicado: (2013) -
Mavrilimumab for severe COVID-19 – Authors' reply
por: De Luca, Giacomo, et al.
Publicado: (2020) -
High mortality co-infections of COVID-19 patients: mucormycosis and other fungal infections
por: Bhatt, Kinal, et al.
Publicado: (2021)